Department of Hematology, The Second Affiliated Hospital of Kunming Medical University.
This clinical trial is positioned to evaluate the efficacy and safety of Venetoclax in combination with a 3-day Decitabine regimen compared to the established Venetoclax and Azacitidine regimen in elderly or unfit patients with newly diagnosed Acute Myeloid Leukemia (AML). The target population is significant, as elderly patients represent a substantial segment of the AML market, often facing limited treatment options due to comorbidities. If successful, this trial could provide a competitive edge for Venetoclax in the AML treatment landscape, potentially expanding its market share against existing therapies. The trial's outcomes may influence treatment guidelines and reimbursement policies, thus impacting commercial strategies for stakeholders involved in AML therapeutics.
Indication: Elderly AML Patients
Modality: combination therapy
Target: BCL-2 inhibition via Venetoclax combined with hypomethylating agents (Decitabine and Azacitidine) to enhance apoptosis in AML cells.
Sponsor: The Second Affiliated Hospital of Kunming Medical University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 02, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: BCL-2 inhibition via Venetoclax combined with hypomethylating agents (Decitabine and Azacitidine) to enhance apoptosis in AML cells.
View original source fields
Condition raw: Elderly AML Patients, Unfit, New-diagnosis AML, Acute Myeloid Leukemia, Venetoclax, Decitabine
Condition normalized: Elderly AML Patients, Unfit, New-diagnosis AML, Acute Myeloid Leukemia, Venetoclax, Decitabine
Modality raw: combination therapy
Modality normalized: combination therapy
Target raw: BCL-2 inhibition via Venetoclax combined with hypomethylating agents (Decitabine and Azacitidine) to enhance apoptosis in AML cells.
Target normalized: BCL-2 inhibition via Venetoclax combined with hypomethylating agents (Decitabine and Azacitidine) to enhance apoptosis in AML cells.